Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?
作者信息
Kotze Paulo Gustavo, Danese Silvio
机构信息
IBD Outpatient Clinics, Colorectal Surgery Unit Health Sciences Postgraduate Program (PPGCS) Catholic University of Parana (PUCPR), Curitiba, Brazil.
Department of Biomedical Sciences, IBD Center Department of Gastroenterology, Humanitas Research Hospital Rozzano, Milan, Italy.
出版信息
Curr Med Chem. 2019;26(2):246-247. doi: 10.2174/092986732602190314161008.
Abstract
摘要
相似文献
1
Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?炎症性肠病中的生物类似药与原研产品：关注差异？
Curr Med Chem. 2019;26(2):246-247. doi: 10.2174/092986732602190314161008.
2
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.在炎症性肠病治疗中，将原研英夫利昔单抗转换为生物类似药的健康相关生活质量及成本
Medicine (Baltimore). 2020 Jan;99(2):e18723. doi: 10.1097/MD.0000000000018723.
3
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.将澳大利亚中重度炎症性肠病患者的英夫利昔单抗原研药换成生物类似药：一项多中心平行队列研究。
Med J Aust. 2021 Feb;214(3):128-133. doi: 10.5694/mja2.50824. Epub 2020 Oct 17.
4
Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.医学访谈对炎症性肠病患者从原研英夫利昔单抗切换到其生物类似药的决策的影响。
Dig Liver Dis. 2020 Mar;52(3):281-288. doi: 10.1016/j.dld.2019.09.012. Epub 2019 Oct 22.
5
Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?炎症性肠病中的生物类似药疗法：我们应该关注患者特征吗？
Expert Rev Clin Immunol. 2016;12(4):361-3. doi: 10.1586/1744666X.2016.1141050. Epub 2016 Feb 8.
6
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.瑞典不同郡的不同政策措施和实践影响市场动态：第 1 部分-生物类似药和原研英夫利昔单抗在医院环境中的应用。
BioDrugs. 2019 Jun;33(3):285-297. doi: 10.1007/s40259-019-00345-6.
7
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.英夫利昔单抗生物类似药CT-P13用于炎症性肠病（IBD）起始治疗或换药治疗的疗效及耐受性：一项大型单中心研究经验
Scand J Gastroenterol. 2018 Jun;53(6):700-707. doi: 10.1080/00365521.2018.1464203. Epub 2018 Apr 24.
8
Biosimilar medicines in inflammatory bowel disease.炎症性肠病中的生物类似药。
Tidsskr Nor Laegeforen. 2014 Apr 29;134(8):819-20. doi: 10.4045/tidsskr.14.0192.
9
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?生物类似药的引入是否改变了我们对炎症性肠病治疗方式的理解？
Dig Dis. 2017;35(1-2):74-82. doi: 10.1159/000449087. Epub 2017 Feb 1.
10
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.炎症性肠病中两个非转换队列患者的英夫利昔单抗浓度：原研药与生物类似药。
Sci Rep. 2020 Oct 13;10(1):17099. doi: 10.1038/s41598-020-74235-1.
Zotero 插件